Data-driven volatility is hardly a new phenomenon in biotech trading. However, a bevy of clinical trial read-outs in recent weeks has prompted some eye-popping moves https://t.co/XwfPysGrqw— Bloomberg (@business) October 24, 2022
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)













Quickly


